免费电话：400-668-6834 | 技术支持：400-168-6834 | 邮箱：info@selleck.cn

Capivasertib (AZD5363)

目录号：S8019

仅限科研使用

Capivasertib (AZD5363)有效抑制Akt(Akt1/Akt2/3)的所有亚型，在无细胞试验中IC50为3 nM/8 nM/8 nM，对P70S6K/PKA也具有相似的抑制效果，而对ROCK1/2抑制活性较低。Phase 2。

Capivasertib (AZD5363) Chemical Structure

CAS: 1143532-39-1

规格	价格	库存
10mM (1mL in DMSO)	RMB 1926.33	现货
5mg	RMB 1216.65	现货
25mg	RMB 3865.98	现货
100mg	RMB 9582.3	现货
大包装	有超大折扣
大剂量询单有大折扣!
今日订购，明日送达全国免运费分装免费分装成小规格产品（单支最小为1mg）如1支10mg产品可分装为10支1mg产品全国免费电话：400-668-6834 \| Email：info@selleck.cn

客户使用Selleck生产的Capivasertib (AZD5363)发表文献101篇：

产品安全说明书

Akt抑制剂选择性比较

生物活性

产品描述

特性

AZD5363具有良好的临床前期耐受性，和AKT抑制剂的药效学特性，且不同于其他AKT抑制剂具有卓越的特性，已经进入临床开发阶段。^[2]

靶点

Akt1 ^[1] (Cell-free assay)	Akt2 ^[1] (Cell-free assay)	Akt3 ^[1] (Cell-free assay)	ROCK2 ^[1] (Cell-free assay)
3 nM	8 nM	8 nM	56 nM

体外研究

AZD5363是有效的Akt抑制剂，抑制Akt1, Akt2 和 Akt3时，IC50分别为3 nM, 8 nM 和 8 nM。PIK3CA突变的激活，肿瘤抑制基因PTEN的丢失或失活，或HER2的扩增，都与AZD5363有着显著的关系。此外，还可以看出细胞系的RAS突变状态与抗AZD5363之间的相关性。^[1]AZD5363在细胞中抑制AKT底物的磷酸化，效价约为0.3〜0.8μM。AZD5363抑制182种实体和血液肿瘤细胞系中的41种细胞增殖，效价为< 3 μM。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

PC-3	MXHGeY5kfGmxbjDBd5NigQ>?	NEDQ[pAyOCEQvF2=	NV7rToNUOTJiaB?=	Ml:2bY5lfWOnczDheZRweGijZ4m=	NIPMZo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K1PFc1OCd-MkOyOVg4PDB:L3G+
LNCaP	M13KfGNmdGxiVnnhZoltcXS7IFHzd4F6	MoD0NE0yODByIH7N	MX2wMVQh\A>?	M2PMdZJm\HWlZXSgUG5E[VBiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVzyqB?	M1TpVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkW4O\|QxLz5{M{K1PFc1ODxxYU6=
DU145	M1;LbWZ2dmO2aX;uJGF{e2G7	M2nEcVAvPS9zL{GwJO69VQ>?	M1;uU\|Q5KGh?	Mknw[I94dnKnZ4XsZZRmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wIH;mJIRwf26\|dILlZY0heGG2aIfhfUBxem:2ZXnud{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ3OEe0NEc,OjN{NUi3OFA9N2F-
PC-3	MVrGeY5kfGmxbjDBd5NigQ>?	MXWwMlUwOS9zMDFOwG0>	MnziOFghcA>?	NVPzVnY6\G:5boLl[5Vt[XSnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKGSxd37zeJJm[W1icHH0bJdigSCycn;0[YlveyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ3OEe0NEc,OjN{NUi3OFA9N2F-
C4-2	M37zOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYOxNFAuPTByMDDuUS=>	MVm3NkBp	MoT3bY5kemWjc3XzJJRp\SCocnHjeIlwdiCxZjDj[YxteyC3bnTldodwcW6pIHPlcIwh\GWjdHi=	NIrVcIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2OlYzOSd-MkO5OlY3OjF:L3G+
LNCaP	MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3ZNVAxNTVyMECgcm0>	NXn2S4lGPzJiaB?=	MkjDbY5kemWjc3XzJJRp\SCocnHjeIlwdiCxZjDj[YxteyC3bnTldodwcW6pIHPlcIwh\GWjdHi=	MoD5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7Nk[2NlEoRjJ\|OU[2OlIyRC:jPh?=
C4-2	NFH2co9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXyxMVExODByIH7N	NF;OcpIxNTNiZB?=	NVzSWlRUcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	NYXB[3VMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlY3OjFpPkKzPVY3PjJzPD;hQi=>
LNCaP	Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVn0Wo42OS1zMECwNEBvVQ>?	M1nWUVAuOyCm	M{XhNYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	NX7qXmRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlY3OjFpPkKzPVY3PjJzPD;hQi=>
C4-2	M3vsN2Z2dmO2aX;uJGF{e2G7	MlvnOUDPxE1?	NFfPb3ExNTJ2IHi=	MWHpcohq[mm2czDwbI9{eGixconsZZRqd25ib3[geIhmKGSrc4ThcEBCU1RvcHH0bJdigSCkaX;tZZJs\XK\|IHnuZ4x2\GmwZzDQVmFUPDBuIHXJSlRGNCB2RT3CVFEtKG2WT2KsJIFv\CCSN{CgV\|Yhc2mwYYPlJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy	M2LxNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[2OlIyLz5{M{m2OlYzOTxxYU6=
LNCaP	MmXzSpVv[3Srb36gRZN{[Xl?	MlzCOUDPxE1?	MkTrNE0zPCCq	MYrpcohq[mm2czDwbI9{eGixconsZZRqd25ib3[geIhmKGSrc4ThcEBCU1RvcHH0bJdigSCkaX;tZZJs\XK\|IHnuZ4x2\GmwZzDQVmFUPDBuIHXJSlRGNCB2RT3CVFEtKG2WT2KsJIFv\CCSN{CgV\|Yhc2mwYYPlJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy	M{PJWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[2OlIyLz5{M{m2OlYzOTxxYU6=
C4-2	NUPQdHc1TnWwY4Tpc44hSXO\|YYm=	MnnKOUDPxE1?	MlzzNE0zPCCq	MWrpcoR2[2W\|IFHLWHM1PzNiYX7kJGFMXFR\|MEigdIhwe3Cqb4L5cIF1cW:wIHnuJIEhfGmvZTDk[ZBmdmSnboSgcYFvdmW{	NEflSFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2OlYzOSd-MkO5OlY3OjF:L3G+
LNCaP	NX7GUWF2TnWwY4Tpc44hSXO\|YYm=	Mk\tOUDPxE1?	M2HKfFAuOjRiaB?=	NVj4NnZJcW6mdXPld{BCU1SVNEezJIFv\CCDS2TUN\|A5KHCqb4PwbI9zgWyjdHnvckBqdiCjIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>	M3zrTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[2OlIyLz5{M{m2OlYzOTxxYU6=
PAMC82	MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnPVTWM2OD1\|MDFOwG0>	NWjJT5pORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
MKN74	NIDiO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1:5R2lEPTB;M{Cg{txO	NVTpeWRVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
GTL-16	Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXL3XGNjUUN3ME2zNEDPxE1?	M1XSdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi4N\|gzLz5{NEC4PFM5OjxxYU6=
SNU-5	NGfmcZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUTJR\|UxRTNyIN88US=>	NECybZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4PFM5Oid-MkSwPFg{QDJ:L3G+
NUGC-4	MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXzJR\|UxRTNyIN88US=>	NIfRc5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4PFM5Oid-MkSwPFg{QDJ:L3G+
SNU-216	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVrmc45qUUN3ME2zNEDPxE1?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
AZ521	MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1;WdmlEPTB;MkWuOFQ5KM7:TR?=	NX\zcIg5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
NUGC-3	NHK0To9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4\lUGlEPTB;MkGuPFc{KM7:TR?=	M3v3SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi4N\|gzLz5{NEC4PFM5OjxxYU6=
OCUM-1	MlvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVzJR\|UxRTF2LkWxOUDPxE1?	NX7lVJJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
SNU-16	M1L0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NF3ycYNKSzVyPUGxMlA6PyEQvF2=	M3f5eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi4N\|gzLz5{NEC4PFM5OjxxYU6=
SNU-484	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2fRUmlEPTB;Nz6zPVIh\|ryP	M3L4dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi4N\|gzLz5{NEC4PFM5OjxxYU6=
KATO III	NXThW3c1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3Px[mlEPTB;Nz6yOlch\|ryP	Mk\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEizPFIoRjJ2MEi4N\|gzRC:jPh?=
HS746T	Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlP3TWM2OD14LkC4OEDPxE1?	Ml36QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEizPFIoRjJ2MEi4N\|gzRC:jPh?=
SNU-668	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3HGd2lEPTB;Nj6wNFMh\|ryP	NV7WSlZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
SNU-601	NFPuPZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEnkTZhKSzVyPUWuPVM5KM7:TR?=	Mn3SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEizPFIoRjJ2MEi4N\|gzRC:jPh?=
SNU-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGLQO4RKSzVyPUWuNlU5KM7:TR?=	NGrQVGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4PFM5Oid-MkSwPFg{QDJ:L3G+
SNU-638	M2XuT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEnNVpJKSzVyPUSuOVI{KM7:TR?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
SNU-620	NX3z[XdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3nuRWlEPTB;Mz6zPFQh\|ryP	MlTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEizPFIoRjJ2MEi4N\|gzRC:jPh?=
MKN1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{PyeWlEPTB;Mj60NlEh\|ryP	NH25NY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4PFM5Oid-MkSwPFg{QDJ:L3G+
23132/87	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mn3ITWM2OD1zLk[3NUDPxE1?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
NCI-N87	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYrJR\|UxRTFwMEO3JO69VQ>?	MoH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEizPFIoRjJ2MEi4N\|gzRC:jPh?=
AGS	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MorETWM2OD1yLkW1NkDPxE1?	M{LUO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi4N\|gzLz5{NEC4PFM5OjxxYU6=
IM95m	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIPBZlVKSzVyPUCuOVEh\|ryP	M1vLclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi4N\|gzLz5{NEC4PFM5OjxxYU6=
HGC27	M4i1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV3JR\|UxRTBwNES1JO69VQ>?	M3HYVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi4N\|gzLz5{NEC4PFM5OjxxYU6=
PC-9	MUnGeY5kfGmxbjDBd5NigQ>?	NVnDPY41OS93L{GwJO69VQ>?	M2j6SFQwOjRiaB?=	MYDpcoNz\WG\|ZYOgRWtVKHCqb4PwbI9zgWyjdHnvci=>	NHfycpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1O\|Y5Oid-MkS5OVc3QDJ:L3G+
NCI-H522	NVf0ZnE1TnWwY4Tpc44hSXO\|YYm=	MYGxM\|UwOTBizszN	NUfFdIs1PC9{NDDo	MljmbY5kemWjc3XzJGFMXCCyaH;zdIhwenmuYYTpc44>	M4[5elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUW3OlgzLz5{NEm1O\|Y5OjxxYU6=
PC-9	MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoPtTWM2OD17LkOgLOKyOS5{KTFOwG0>	NX\4XIVORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVc3QDJpPkK0PVU4Pjh{PD;hQi=>
NCI-H522	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUHJR\|UxRTFzLkOgLOKyOi55KTFOwG0>	MnrpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUe2PFIoRjJ2OUW3OlgzRC:jPh?=
MR49F	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW[wMVUh\|ryP	NH7GblM1QCCq	NGC1bWpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NI\NSmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1NVAyOid-MkWxOVExOTJ:L3G+
MR49C	M2\pXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLWNE02KM7:TR?=	NUHNN2x3PDhiaB?=	M370O4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NFvT[XI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1NVAyOid-MkWxOVExOTJ:L3G+
SKBR3	NHTMOJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWewMVEvOzVizszN	MoXROUBl	MX7lcohidmOnczD0bIUh\3Kxd4ToJIlvcGmkaYTpc44hd2ZiQWrEPFk{OQ>?	M1yxXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEm1OFc2Lz5{NkC5OVQ4PTxxYU6=
KPL4	MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7GNE0yNjN3IN88US=>	MWq1JIQ>	MoHP[Y5p[W6lZYOgeIhmKGe{b4f0bEBqdmirYnn0bY9vKG:oIFHaSFg6OzF?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB7NUS3OUc,OjZyOUW0O\|U9N2F-
BT474c	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;NWphHOC1zLkO1JO69VQ>?	MkXROUBl	MkjR[Y5p[W6lZYOgeIhmKGe{b4f0bEBqdmirYnn0bY9vKG:oIFHaSFg6OzF?	M1KxZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEm1OFc2Lz5{NkC5OVQ4PTxxYU6=
HCC1954	NFKxU4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjjNE0yNjN3IN88US=>	NHfqTpQ2KGR?	NUTub2xt\W6qYX7j[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJGFbTDh7M{G=	NVXscGJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPVU1PzVpPkK2NFk2PDd3PD;hQi=>
TamR	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37ReVQxOCCwTR?=	MYm2JIQ>	M{jMdolv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?=	NESz[2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1NVMzOyd-Mk[zOVE{OjN:L3G+
T74D LTED	NEfLbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LmXFExOCCwTR?=	M2jURVYh\A>?	M1f3d4lv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?=	M2jIU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{WxN\|I{Lz5{NkO1NVMzOzxxYU6=
ZR75 LTED	M1fsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUOxNFAhdk1?	NGXrR4Q3KGR?	MkLubY5kemWjc3XkJIRzfWdic3Xud4l1cX[rdImgc4YhPC2RSGSgZY5lKG[3bI\ld5Rz[W62	NEfFbo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1NVMzOyd-Mk[zOVE{OjN:L3G+
MCF7 LTED	M3v3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV[yNFAhdk1?	M1PKWlYh\A>?	NFrYTHJqdmO{ZXHz[YQh\HK3ZzDz[Y5{cXSrdnn0fUBw\iB2LV;IWEBidmRiZoXseoV{fHKjboS=	MlT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NUGzNlMoRjJ4M{WxN\|I{RC:jPh?=
1%MCF7	M4LtbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYe0NFAhdk1?	NXe0SI14PiCm	MXvpcoNz\WG\|ZXSg[JJ2\yC\|ZX7zbZRqfmm2eTDv[kA1NU:KVDDhcoQh\nWudnXzeJJidnR?	NYrsVY5DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVE{OjNpPkK2N\|UyOzJ\|PD;hQi=>
T74D	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHJNVAxKG6P	MnjTOkBl	NVLpWIh[cW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70	NG\wUHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1NVMzOyd-Mk[zOVE{OjN:L3G+
ZR75	NHjTbWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DJe\|ExOCCwTR?=	MWm2JIQ>	MX\pcoNz\WG\|ZXSg[JJ2\yC\|ZX7zbZRqfmm2eTDv[kA1NU:KVDDhcoQh\nWudnXzeJJidnR?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3MUOyN{c,OjZ\|NUGzNlM9N2F-
MCF7	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHT1WGUzODBibl2=	MWi2JIQ>	NXTyVJRYcW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3MUOyN{c,OjZ\|NUGzNlM9N2F-
LNCaP	MVXGeY5kfGmxbjDhd5NigQ>?			NEHCU3pKdmirYnn0bY9vKG:oIFHreEBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDMUmNiWCClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhwenmuYYTpc44hd2ZiR2PLN4JmfGFuIFnDOVAhRSByLkC2JO69VS5?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN7NEKxPEc,OjN\|OUSyNVg9N2F-
MDA-MB-468	M3mxS2Z2dmO2aX;uJIF{e2G7		MlvrNkBpenN?	Mk\BTY5pcWKrdHnvckBw\iCDa4SgbY4hcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFfTT\|Nj\XSjIIDoc5NxcG:{eXzheIlwdiCjZoTldkAzKGi{czDifUBt[XOncjDzZ4FvdmmwZzDjfZRwdWW2comsJGlEPTBiPTCwMlA5QSEQvF2u	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN7NEKxPEc,OjN\|OUSyNVg9N2F-
LNCaP	NF;NZVRHfW6ldHnvckBie3OjeR?=			Mln4TY5pcWKrdHnvckBw\iCDa4SgbY4hWFSHTj3k[YZq[2mnboSgbJVu[W5iTF7DZXAh[2WubIOgZZN{\XO\|ZXSgZZMheGixc4Doc5J6dGG2aX;uJI9nKFCUQWO0NEwhUUN3MDC9JFAvOjJizszNMi=>	M3X0c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{m0NlE5Lz5{M{O5OFIyQDxxYU6=
BT474c	MUjGeY5kfGmxbjDhd5NigQ>?			NXnnOIZoUW6qaXLpeIlwdiCxZjDBb5QhcW5iaIXtZY4hSlR2N{TjJINmdGy\|IHjhdoJwemmwZzDISXIzMy:SSVuzR2Eh\G:3YnzlJI12fGGwdDDhd5Nme3OnZDDhd{BxcG:\|cHjvdplt[XSrb36gc4YhWFKDU{SwMEBKSzVyIE2gNE4{OSEQvF2u	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN7NEKxPEc,OjN\|OUSyNVg9N2F-
MDA-MB-468	MlnISpVv[3Srb36gZZN{[Xl?			M{fDemlvcGmkaYTpc44hd2ZiQXv0JIlvKFCWRV6t[IVncWOrZX70JIh2dWGwIF3ERU1OSi12NkigZ4VtdHNiYYPz[ZN{\WRiYYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGdUUzOkZYThMEBKSzVyIE2gNE4{QCEQvF2u	NXLLeYFsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVQzOThpPkKzN\|k1OjF6PD;hQi=>
MDA-MB-468	M3rHeWZ2dmO2aX;uJIF{e2G7			NXXQW4hGUW6qaXLpeIlwdiCxZjDBb5QhcW5iUGTFUk1l\W[rY3nlcpQhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDhd5Nme3OnZDDhd{BxcG:\|cHjvdplt[XSrb36gc4YhWFKDU{SwMEBKSzVyIE2gNE4{QSEQvF2u	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN7NEKxPEc,OjN\|OUSyNVg9N2F-
BT474c	MoHlSpVv[3Srb36gZZN{[Xl?			M4Lpc2lvcGmkaYTpc44hd2ZiQXv0JIlvKGi3bXHuJGJVPDd2YzDj[YxteyCqYYLic5JqdmdiSFXSNkswWEmNM1PBJIRwfWKuZTDteZRidnRiYYPz[ZN{\WRiYYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGdUUzOkZYThMEBKSzVyIE2gNE44PiEQvF2u	M17KcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{m0NlE5Lz5{M{O5OFIyQDxxYU6=
RT4	NFfsNIVHfW6ldHnvckBie3OjeR?=			NYq1VJJpUW6qaXLpeIlwdiCxZjDQT2EhcW5iVGPDNUBl\W[rY3nlcpQhcHWvYX6gVnQ1KGOnbHzzJIF{e2W\|c3XkJIF{KFN4IIDoc5NxcG:{eXzheIlwdixiSVO1NEA:KDFizszNMi=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN7NEKxPEc,OjN\|OUSyNVg9N2F-
RT4	M1TJbmZ2dmO2aX;uJIF{e2G7			NVfLdYF7UW6qaXLpeIlwdiCxZjDQO\|BUPktiaX6gWHNEOSCmZX\pZ4lmdnRiaIXtZY4hWlR2IHPlcIx{KGG\|c3Xzd4VlKGG\|IGO2JJBpd3OyaH;yfYxifGmxbjygTWM2OCB;IEWg{txONg>?	M1HWdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{m0NlE5Lz5{M{O5OFIyQDxxYU6=
PTEN-null LNCAP	MoHFSpVv[3Srb36gZZN{[Xl?		MU[xJIhz	M2W1NmlvcGmkaYTpc44hd2ZiQXv0JIlvKGi3bXHuJHBVTU5vboXscEBNVkODUDDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW\|c3nvckBqdiCSUlHTOFAheGixc4Doc5J6dGG2aX;uJIFnfGW{IEGgbJIh[nliRVzJV2Eh[W6jbInzbZMtKEmFNUCgQUAxNjN\|Nkig{txONg>?	NVG5VWJ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewPFkzOTFpPkK3NFg6OjFzPD;hQi=>
HCT116	Mnn4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NF\WfFI4OiCqcoO=	NUWzepdvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFUvOiEQvF2u	MmnoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyOEmyNVEoRjJ5MEi5NlEyRC:jPh?=
OVCAR8	NVnUOIJpSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NXv3ZXRtPzJiaILz	NIXzWnJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF;WR2FTQCClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gO{4zPyEQvF2u	NGPyWlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C4PVIyOSd-MkewPFkzOTF:L3G+
A673	MkjHdWhVWyCjc4PhfS=>			MVrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	NYLPNnl6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY	NFHBSphyUFSVIHHzd4F6			MoKzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	NUHON2xpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	NVL4OIVEeUiWUzDhd5NigQ>?			MYTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	NVT0[ZFlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	M1PBOJFJXFNiYYPzZZk>			MmPNdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	NXrUcXJkeUiWUzDhd5NigQ>?			MmWwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	NWfRbYFKeUiWUzDhd5NigQ>?			MmnXdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy\|	NIO0VYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	MYfxTHRUKGG\|c3H5			M4DUNpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|	NUXJSpdyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	NW\mWHV3eUiWUzDhd5NigQ>?			MnnqdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	M2X3ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	M37MWJFJXFNiYYPzZZk>			NGrBT\|FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=>	MlXYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	MXzxTHRUKGG\|c3H5			MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	NFTib3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	M{HOSJFJXFNiYYPzZZk>			NWPDZYxYeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	pAKT / AKT / pGSK3β / GSK3β HER3 / pHER3 / HER2 / pHER2 / pPRAS40 / pS6 / p-4EBP1 / pFOXO / pERK / PARP / Cleaved PARP	26998062 26095475
Immunofluorescence	p-Chk2 / γ-H2AX	29879757
Growth inhibition assay	Cell viability	29879757

体内研究

AZD5363按100, 300 mg/kg剂量口服给药裸鼠，降低BT474c移植瘤中PRAS40, GSK3β,和 S6的磷酸化，这种作用具有剂量和时间依赖性，也可逆性地增加血糖浓度，且降低U87-MG移植瘤中2[¹⁸F]氟-2-脱氧-d-葡萄糖(¹⁸F-FDG)的摄取，这种作用存在剂量依赖性。AZD5363按130, 200, 和300 mg/kg剂量慢性口服给药从各种肿瘤类型衍生的移植瘤，包括抗Trastuzumab的HER2⁺乳腺癌模型，抑制移植瘤的生长，这种作用存在剂量依赖性。AZD5363在乳腺癌移植瘤中也显著增强 Docetaxel, Lapatinib, 和 Trastuzumab的抗肿瘤活性。^[2]

激酶实验：^[1]	Caliper Off-Chip Incubation迁移率变动分析: 通过 Caliper Off-Chip Incubation迁移率变动分析测评AZD5363和其他化合物抑制AKT1, AKT2, 和 AKT3活性的能力。活跃的重组AKT1，AKT2，或AKT3与5-FAM标记的定制合成的肽底物，及浓度不断增加的抑制剂温育。最终反应包含1 到 3 nM AKT1, AKT2, 或AKT3 酶; 1.5 mM 肽底物; AKT亚型的ATP为K_m; 10 mM MgCl₂, 4 mM DTT, 100 mM HEPES, 及0.015% Brij-35。反应在室温下温育1小时，然后加入含100 mM HEPES, 0.015% Brij-35 溶液, 0.1% 涂层试剂， 40 mM EDTA, 和5% DMSO的buffer终止反应。使用Caliper LC3000分析实验板，进行肽底物的分离，对磷酸化的产物进行电泳和激光诱导荧光的检测和量化。
细胞实验： ^[2]	Cell lines: 182种实体和血液肿瘤细胞系 Concentrations: 0.003 μM-30 μM Incubation Time: 72 小时 Method: 通过MTS和Sytox Green2种方法测定细胞增殖实验。细胞接种在96孔板中，在37°C下,含 5% CO₂的环境中温育过夜。使用浓度为30 到 0.003μM的 AZD5363处理细胞72小时。对于MTS端点，通过CellTiter AQueous非放射性细胞增殖检测试剂测量细胞增殖。对于Sytox Green 端点，在TBS-EDTA buffer 中稀释的Sytox Green核酸染料加到细胞中（终浓度为0.13μM），使用Acumen Explorer测定死亡细胞数。通过加入Saponin（终浓度0.03％，在TBS-EDTA buffer中稀释）使细胞具有渗透性，温育过夜，并测量总细胞数。MTS 和Sytox Green 端点都是给药前测量，使用吸光度读数（MTS）或活细胞计数测定将实验组细胞的生长降低到未处理组细胞的一半所需要的浓度值。
动物实验：^[2]	Animal Models: 携带 BT474c, U87MG, KPL-4, HCC-1187 移植瘤的雌性裸鼠和雄性SCID小鼠 Dosages: 130 mg/Kg-300 mg/Kg Administration: 口服处理

参考文献	[1] Addie M, et al. J Med Chem, 2013, 26. [2] Davies BR, et al. Mol Cancer Ther, 2012, 11(4), 873-887.

溶解度（25°C）

体外

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量	428.92
化学式	C₂₁H₂₅ClN₆O₂
CAS号	1143532-39-1
储存条件	3年	-20°C	粉状
储存条件	2年	-80°C	溶于溶剂

Download Capivasertib (AZD5363) SDF

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

临床试验信息

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03310541	Active not recruiting	Drug: AZD5363\|Drug: Enzalutamide\|Drug: Fulvestrant	Breast Cancer\|Prostate Cancer\|Advanced Solid Tumors	Memorial Sloan Kettering Cancer Center	October 11 2017	Phase 1
NCT01992952	Active not recruiting	Drug: AZD5363\|Drug: Placebo\|Drug: Fulvestrant	Estrogen Receptor Positive Breast Cancer	Velindre NHS Trust\|AstraZeneca\|Cenduit LLC\|Covance\|Cardiff and Vale University Health Board	May 2014	Phase 1\|Phase 2
NCT02338622	Completed	Drug: olaparib\|Drug: AZD5363	Advanced Cancer	Royal Marsden NHS Foundation Trust\|Institute of Cancer Research United Kingdom\|AstraZeneca	March 31 2014	Phase 1
NCT02121639	Active not recruiting	Drug: Placebo\|Drug: AZD5363	Prostate Cancer	University Hospital Southampton NHS Foundation Trust\|AstraZeneca\|Cancer Research UK	January 29 2014	Phase 1\|Phase 2
NCT02077569	Completed	Drug: AZD5363	Invasive Breast Cancer	University of Nottingham\|AstraZeneca\|Cancer Research UK\|National Cancer Research Network	January 2014	Phase 2
NCT01692262	Completed	Drug: Intermittent dosing of AZD5363	Metastatic Castrate-Resistant Prostate Cancer (mCRPC)\|Efficacy\|Safety and Tolerability\|Pharmacokinetics\|Pharmacodynamics\|Tumour Response.	AstraZeneca	November 2012	Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

* 姓名 请输入您的姓名

* 邮箱 请输入您的邮箱地址 请输入一个有效的邮箱地址

电话

* 留言内容 请写点东西给我们

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):